Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VATCH: Alpelisib in TIE2/PIK3CA Pathway Driven Vascular Anomalies
NCT07543822Phase 2Recruiting
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Aug 2025
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib in Vascular anomalies, sponsored by Children's Hospital of Philadelphia. Started Aug 2025; status: recruiting.
02
Drugs
alpelisib
03
Conditions
Vascular anomalies
Beyond the preview
Go deeper on NCT07543822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07543822.